Getting your player ready...
Data from a study by a team of researchers at the University of Denver shows promise in delaying the onset of Lou Gehrig’s disease, according to information released today by Immunotec Inc.
Using proprietary technology known as Immunocal in a mouse model, the team studied mice harboring the gene responsible for some forms of amyotrophic lateral sclerosis, ALS, and found evidence it preserved blood gluthathione levels that typically diminish in mice affected with the gene.
ALS afflicts about 33,000 people in the U.S. and Canada yearly and is fatal. About 80 percent die within five years of diagnosis.
Daniel Linseman is heading the DU research team.
